Drug Approval | August 06, 2025
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Athena is also exploring the use of this technology for expanded carrier screening
Vasograin Plus represents a major advancement in the treatment of migraine
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
This will be Aster’s fifth hospital in Bengaluru
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Subscribe To Our Newsletter & Stay Updated
